LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: PARP inhibitors: enhancing efficacy through rational combinations.

Bhamidipati, Deepak / Haro-Silerio, Jaime I / Yap, Timothy A / Ngoi, Natalie

British journal of cancer

2023  Volume 129, Issue 6, Page(s) 904–916

Abstract: Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment landscape for tumours harbouring defects in genes involved in homologous repair (HR) such as BRCA1 and BRCA2. Despite initial responsiveness to PARPi, tumours ... ...

Abstract Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment landscape for tumours harbouring defects in genes involved in homologous repair (HR) such as BRCA1 and BRCA2. Despite initial responsiveness to PARPi, tumours eventually develop resistance through a variety of mechanisms. Rational combination strategies involving PARPi have been explored and are in various stages of clinical development. PARPi combinations have the potential to enhance efficacy through synergistic activity, and also potentially sensitise innately PARPi-resistant tumours to PARPi. Initial combinations involving PARPi with chemotherapy were hindered by significant overlapping haematologic toxicity, but newer combinations with fewer toxicities and more targeted approaches are undergoing evaluation. In this review, we discuss the mechanisms of PARPi resistance and review the rationale and clinical evidence for various PARPi combinations including combinations with chemotherapy, immunotherapy, and targeted therapies. We also highlight emerging PARPi combinations with promising preclinical evidence.
MeSH term(s) Female ; Humans ; Genes, BRCA2 ; Neoplasms/drug therapy ; Neoplasms/genetics ; Ovarian Neoplasms/genetics ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
Chemical Substances Poly(ADP-ribose) Polymerase Inhibitors
Language English
Publishing date 2023-07-10
Publishing country England
Document type Journal Article ; Review
ZDB-ID 80075-2
ISSN 1532-1827 ; 0007-0920
ISSN (online) 1532-1827
ISSN 0007-0920
DOI 10.1038/s41416-023-02326-7
Shelf mark
Uh III Zs.142: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top